Integrated Biopharma (Integrated Biopharma) Debt-to-Equity : 0.11 (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma Debt-to-Equity?

Integrated Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.95 Mil. Integrated Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.09 Mil. Integrated Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $18.91 Mil. Integrated Biopharma's debt to equity for the quarter that ended in Mar. 2024 was 0.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Integrated Biopharma's Debt-to-Equity or its related term are showing as below:

INBP' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.78 Med: 0.13 Max: 45.48
Current: 0.11

During the past 13 years, the highest Debt-to-Equity Ratio of Integrated Biopharma was 45.48. The lowest was -2.78. And the median was 0.13.

INBP's Debt-to-Equity is ranked better than
79.09% of 1645 companies
in the Consumer Packaged Goods industry
Industry Median: 0.41 vs INBP: 0.11

Integrated Biopharma Debt-to-Equity Historical Data

The historical data trend for Integrated Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma Debt-to-Equity Chart

Integrated Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

6.81

1.84

0.42

0.11

0.14

Integrated Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.16	0.14	0.13	0.12	0.11

Competitive Comparison of Integrated Biopharma's Debt-to-Equity

For the Packaged Foods subindustry, Integrated Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Biopharma's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's Debt-to-Equity falls into.

Integrated Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Integrated Biopharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.93	+	1.742)	/	18.861
	=	0.14

Integrated Biopharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.953	+	1.086)	/	18.911
	=	0.11

Integrated Biopharma (OTCPK:INBP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Integrated Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Biopharma (Integrated Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Long Avenue, Building 15, Hillside, NJ, USA, 07205

Website

http://www.ibiopharma.com

Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.

Executives

Damon Desantis	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe	director, 10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca	director	72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay	director, 10 percent owner, officer: Chairman and CEO	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker	director	STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach	director, officer: President and CEO
Glenn Chang	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov	director	C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc	10 percent owner	3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva	director, officer: Vice President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay	director, officer: Vive President	C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick	director	C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay	director	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi	officer: Chief Financial Officer	14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis	director, 10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431